Guanfacine

• Description:

  Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) [1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H301, H311, H331

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease; Endocrinology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/guanfacine.html

• Concentration:

  10mM

• Purity:

  99.85

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(NC(N)=N)CC1=C(Cl)C=CC=C1Cl

• Molecular Formula:

  C9H9Cl2N3O

• Molecular Weight:

  246.09

• Precautions:

  H301, H311, H331

• References & Citations:

  [1]Amy F T Arnsten, et al. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85 (1) :45-58. Epub 2012 Mar 29.|[2]P. A. Van Zwieten, et al. The pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol. 1983; 15 (Suppl 4) : 455S–462S. |[3]Min Wang, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007 Apr 20;129 (2) :397-410.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  α adrenergic receptor

• Citation 01:

  Nat Commun. 2025 May 16;16 (1) :4560.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Patent. US20230147129A1.

• CAS Number:

  [29110-47-2]